Business Wire

NY-APTORUM-GROUP-LIMITED

10.2.2020 14:02:07 CET | Business Wire | Press release

Share
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma, a rare type of childhood cancer that develops in infants and young children. Subject to completion of current validation studies, Aptorum Group plans to leverage the 505(b)(2) pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.1

SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACTTM drug discovery platform, which employs a systematic approach to identify, repurpose and develop existing approved drugs against a currently identified universe of 7000+ (and increasing) orphan diseases.2

Through this platform, Aptorum Group intends to accelerate and fast track repurposed drug candidates, which usually have well established human safety and toxicity profiles and data, through the development and clinical phases in order to address the rapidly growing market of orphan diseases. Aptorum Group aims to screen a number of orphan disease areas including, but not limited to, oncology, autoimmune, metabolic and genetic diseases.

Through the Smart-ACTTM platform, Aptorum has successfully identified potential efficacy for and develops SACT-1 for the treatment of neuroblastoma, being an entirely new therapeutic area from its approved indication. In our recent studies, SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent the high-risk neuroblastoma patient group. In addition, by using a combination index as a quantitative measure of the extent of drug interaction, Aptorum Group has seen a high and robust synergism between SACT-1 and traditional chemotherapy in vitro, indicating a potential efficacy enhancement/dose reduction of the chemotherapy. In addition, in our recent study, the maximum tolerable dose of SACT-1 in a rodent model was determined to be higher than 400mg/kg. Compared with the MTD of standard chemotherapy such as paclitaxel (20-30mg/kg)3 and cisplatin (6mg/kg) 4 , the safety profile of SACT-1 appears to be very impressive.

The reformulation of SACT-1 is a pediatric formulation to better address the needs of neuroblastoma patients who are exclusively children younger than 5. Based on our internal observations of pre-existing information from approved products,5 SACT-1 also exhibits a well-established safety profile: at 150mg/day, the death rate was 0% in prior clinical studies) with no dosage related adverse events.

About neuroblastoma

Neuroblastoma is a rare form of cancer, and classified as an orphan disease, that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, predominantly in children, especially for those aged 5 years and below. For the high-risk group, which is close to 20%6 of total new patient population per year, the 5-year survival rate of this condition is around 40-50% as observed by the American Cancer Society7 . The current high drug treatment cost for high risk patients can average USD200,000 per regimen (all 6 cycles)8 . In addition, most pediatric patients often do not tolerate or survive the relevant chemotherapy stage which, subject to further clinical studies, may be positively addressed by the SACT-1 candidate due to the potential synergistic effects when applied with standard chemotherapy as described above.

For further general presentation, please visit: http://ir.aptorumgroup.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16

For further technical presentation, please visit: http://ir.aptorumgroup.com/static-files/66346f79-7a03-474a-89be-0eaafaa00d9d

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases and other disease areas.

For more information about Aptorum Group, please visit www.aptorumgroup.com .

About Smart Pharma Group

Smart Pharma Group is wholly owned by Aptorum Group Limited. Smart Pharma Group focuses on systematically identifying and repurposing existing approved drugs for the treatment of a large array of orphan diseases. Smart Pharma Group conducts both computational based screening and clinical validations in advancing the development of its repurposed candidates.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


1 If the FDA deems the 505(b)(2) pathway as an acceptable route for approval of SACT-1, the Company will be able to leverage existing clinical and nonclinical data in conjunction with sponsor-initiated studies to accelerate development and approval of SACT-1.
2 See https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases
3 Clin Cancer Res. 5(11):3632-8.
4 BMC Cancer 17: 684 (2017).
5 Subject to FDA's approval and on a case-by-case basis, a 505(b)(2) application can rely in part on existing information from approved products (such as the FDA's previous findings on safety and efficacy) or products in literature (such as data available). However, typically speaking, the applicant is nonetheless required to carry out a Phase 1 bridging study to compare the Reference Listed Drug and reference the established safety and efficacy information.
6 Annu Rev Med. 2015; 66: 49–63.
7 https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html
8 https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release

Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye